Emerging Heterocyclic Compounds for the Management of Prostate Cancer
DOI:
https://doi.org/10.21276/apjhs.2021.8.4S.9Keywords:
Emerging heterocyclic, Prostate cancer (PCa), Non-androgenic drugs, Anti-proliferative agents, Cytotoxic, PC3-cellsAbstract
Background: This review is an overview of emerging heterocyclic compound classes that might give a safe and effective treatment for prostate cancer.
Main body: Most heterocyclic compounds or heterocyclic fragments present in most of the anticancer pharmaceuticals presently in market and are versatile with unique physicochemical properties. Most of anticancer research is being capitalized on the intrinsic versatility and dynamic core of heterocyclic compounds. In this review we shall focus on moieties that are suitable for prostate cancer therapy along with addressing their biochemical modes of action, biological targets, structure-activity relationship and intrinsic drawbacks in the use of these compounds
Conclusion: These classes and their derivatives discussed here might provide a novel drug therapy for cancer treatment.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Manish Chaudhary, Deepali Gupta, Saumik Chaudhury, Paranjeet Kaur
This work is licensed under a Creative Commons Attribution 4.0 International License.
Asian Pacific Journal of Health Sciences applies the Creative Commons Attribution (CC-BY) license to published articles. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. Appropriate attribution can be provided by simply citing the original article.